ArticleESMO open2021
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.
Article in ESMO open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis.Breast (Edinburgh, Scotland) · 2023Pooled it
- Physical and mental health outcomes of COVID-19 induced delay in oncological care: A systematic review.Frontiers in oncology · 2023Pooled it
- Article
- Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period.Journal of managed care & specialty pharmacy · 2026Article
- Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohort.Scientific reports · 2026Article
- COVID-19 pandemic interruption of breast cancer screening is linked to clinical upstaging at presentation: the roles of demographics, socioeconomic status and unmet social needs.Breast cancer research and treatment · 2025Observational
- A Nationwide Exploration of Social Inequalities in Cancer Mortality Amidst the COVID-19 Pandemic in Belgium.Cancer medicine · 2025Article
- Healthcare use among cancer survivors during the COVID-19 pandemic: results from the SHARE COVID-19 Survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Article
- Impact of the COVID-19 Pandemic on Thyroid Cancer Surgery.Current oncology (Toronto, Ont.) · 2024Article
- Regional excess mortality in France during COVID-19 pandemic: the first three epidemic periods (March 2020-June 2021).European journal of public health · 2024Article
- Impact of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- The impact of the COVID-19 pandemic on neurosurgery in the elderly population in Sweden.BMC public health · 2024Observational
- Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.PloS one · 2024Article
- Excess mortality in adults from Sao Paulo during the COVID-19 pandemic in 2020: analyses of all-cause and noncommunicable diseases mortality.Scientific reports · 2023Article
- Article
- Article
- Changes in the Utilization of Health Care Services by Cancer Patients during the COVID-19 Pandemic.Yonsei medical journal · 2023Article
- Early survival for patients newly diagnosed with cancer during COVID-19 in Ontario, Canada: A population-based cohort study.Cancer medicine · 2023Article
- Estimating Excess Mortality Due to Prostate, Breast, and Uterus Cancer during the COVID-19 Pandemic in Peru: A Time Series Analysis.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 19 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of the first coronavirus disease 2019 (COVID-19) wave on cancer patient management was measured within the nationwide network of the Unicancer comprehensive cancer centers in France. PATIENTS AND
methodsThe number of patients diagnosed and treated within 17 of the 18 Unicancer centers was collected in 2020 and compared with that during the same periods between 2016 and 2019. Unicancer centers treat close to 20% of cancer patients in France yearly. The reduction in the number of patients attending the Unicancer centers was analyzed per regions and cancer types. The impact of delayed care on cancer-related deaths was calculated based on different hypotheses.
resultsA 6.8% decrease in patients managed within Unicancer in the first 7 months of 2020 versus 2019 was observed. This reduction reached 21% during April and May, and was not compensated in June and July, nor later until November 2020. This reduction was observed only for newly diagnosed patients, while the clinical activity for previously diagnosed patients increased by 4% similar to previous years. The reduction was more pronounced in women, in breast and prostate cancers, and for patients without metastasis. Using an estimated hazard ratio of 1.06 per month of delay in diagnosis and treatment of new patients, we calculated that the delays observed in the 5-month period from March to July 2020 may result in an excess mortality due to cancer of 1000-6000 patients in coming years.
conclusionsIn this study, the delays in cancer patient management were observed only for newly diagnosed patients, more frequently in women, for breast cancer, prostate cancer, and nonmetastatic cancers. These delays may result is an excess risk of cancer-related deaths in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.